The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins
Open accessAbstract
Background Plasma apolipoprotein B (apoB) is a composite measure of all apoB-containing lipoproteins causing atherosclerotic cardiovascular disease; however, it is unclear which fraction of risk is explained by cholesterol and triglycerides, respectively, in very low-density lipoproteins (VLDLs). Objectives The authors tested the hypothesis that VLDL cholesterol and triglycerides each explain part of the myocardial infarction risk from apoB-containing lipoproteins. Methods Nested within 109,751 individuals from the Copenhagen General Population Study, the authors examined 25,480 subjects free of lipid-lowering therapy and myocardial infarction at study entry. All had measurements of plasma apoB (quantitating number of apoB-containing lipoproteins) and cholesterol and triglyceride content of VLDL, intermediate-density lipoproteins (IDLs), and low-density lipoproteins (LDLs). Results During a median 11 years of follow-up, 1,816 were diagnosed with myocardial infarction. Per 1-mmol/l higher levels, multivariable-adjusted hazard ratios for myocardial infarction were 2.07 (95% confidence interval [CI]: 1.81 to 2.36) for VLDL cholesterol, 1.19 (95% CI: 1.14 to 1.25) for VLDL triglycerides, 5.38 (95% CI: 3.73 to 7.75) for IDL cholesterol, and 1.86 (95% CI: 1.62 to 2.14) for LDL cholesterol. Per 1-g/l higher plasma apoB, the corresponding value was 2.21 (95% CI: 1.90 to 2.58). In a step-up Cox regression, risk factors for myocardial infarction entered by importance as VLDL cholesterol, systolic blood pressure, smoking, and IDL + LDL cholesterol, whereas VLDL triglycerides did not enter the model. VLDL cholesterol explained 50% and IDL + LDL cholesterol 29% of the risk of myocardial infarction from apoB-containing lipoproteins, whereas VLDL triglycerides did not explain risk. Conclusions VLDL cholesterol explained one-half of the myocardial infarction risk from elevated apoB-containing lipoproteins, whereas VLDL triglycerides did not explain risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have suggested that TG and remnant cholesterol may be more potent risk factors for myocardial infarction (MI) than LDL-C is.2,3”
From Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
The Danish Civil Registration System
Pedersen, C. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810387965 · Cited by 4,713
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–175 of 175
Klobučar, I., Habisch, H., Klobučar, L., Trbušić, M., Pregartner, G., Berghold, A., Kostner, G. M., Scharnagl, H., Madl, T., Frank, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095050 · Cited by 7
Sørensen, I. M. H., Bisgaard, L. S., Bjergfelt, S. S., Ballegaard, E. L. F., Biering‐Sørensen, T., Landler, N. E., Pedersen, T. X., Kofoed, K. F., Lange, T., Feldt‐Rasmussen, B., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.019 · Cited by 8
Xin-Ji-Er-Kang protects heart from ischemia-reperfusion injury by rebalancing lipid metabolism
Sun, L.-J., Wang, X., Xia, J. L., Xu, Y.-M., Liao, Y.-F., Qin, Y.-Y., Ge, X.-W., Zhao, P.-W., Xu, T., Zhu, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.981766 · Cited by 6
Degoricija, V., Klobučar, I., Potočnjak, I., Terešak, S. D., Vidović, L., Pregartner, G., Berghold, A., Habisch, H., Madl, T., & Frank, S. (2022) · Biomolecules · doi:10.3390/biom12101542 · Cited by 6
bubbleHeatmap: an R package for visualization of Nightingale Health metabolomics datasets
Boxall, R., Holmes, M. V., & Walters, R. G. (2023) · Bioinformatics Advances · doi:10.1093/bioadv/vbad123 · Cited by 6
Millar, S., Navarro, P., Harrington, J. M., Perry, I. J., & Phillips, C. M. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117559 · Cited by 6
Liu, Y., Skudder‐Hill, L., Kimita, W., Shamaitijiang, X., Sequeira, I. R., & Petrov, M. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16338 · Cited by 6
Engell, A. E., Bathum, L., Siersma, V., Andersen, C. L., Lind, B., & Jørgensen, H. L. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02607-5 · Cited by 7
Cardioprotective Effects of Nutraceuticals: Focus on Omega-3 Polyunsaturated Fatty Acids
Sypniewska, G., & Kruszewski, S. (2021) · Nutrients · doi:10.3390/nu13093184 · Cited by 6
Diagnosis of remnant hyperlipidaemia
Paquette, M., Bernard, S., & Baass, A. W. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000831 · Cited by 6
Manikpurage, H. D., Ricard, J., Houessou, U., Bourgault, J., Gagnon, É., Gobeil, É., Girard, A. S., Li, Z., Eslami, A., Mathieu, P., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119083 · Cited by 6
Kirwan, R., Mazidi, M., Butler, T., de Heredia, F. P., Lip, G. Y. H., & Davies, I. G. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae019 · Cited by 5
Toffol, E., Heikinheimo, O., Jousilahti, P., Lehtoranta, L., Joensuu, A., Partonen, T., Erlund, I., & Haukka, J. K. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae318 · Cited by 5
Examining Predictors of Myocardial Infarction
Dolezel, D. M., McLeod, A. J., Jr., & Fulton, L. V. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111284 · Cited by 5
Remnant Lipoproteins as a Target for Atherosclerosis Risk Reduction
Levin, M. G. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316341 · Cited by 5
Huang, Q., Zhang, H., Shen, Z., Chen, J., Cao, X., Xu, L., Zhu, C., Lv, S., Yu, X., Ding, X., et al. (2025) · Phenomics · doi:10.1007/s43657-024-00179-5 · Cited by 4
Chen, L.-J., Herder, C., Xie, R., Brenner, H., & Schöttker, B. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112108 · Cited by 4
Genedy, N., & Zouwail, S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.008 · Cited by 4
Ding, Y., Yang, S., He, M., Fan, S., Tao, X., & Lü, W. (2023) · Metabolites · doi:10.3390/metabo13090976 · Cited by 4
Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease
Pencina, K. M., Pencina, M. J., Lawler, P. R., Engert, J. C., Dufresne, L., Ridker, P. M., Thanassoulis, G., Mora, S., & Sniderman, A. D. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac172 · Cited by 4
Zhang, P., Ma, J., Li, D., Li, Q., Qi, Z., Xu, P., Liu, L., Li, H., & Zhang, A. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0101 · Cited by 4
Walking the VLDL tightrope in cardiometabolic diseases
Kim, M., & Zheng, Z. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.020 · Cited by 4
Mickelsson, M., Liv, P., Stefansson, K., Ekblom, K., Själander, A., Nyman, E., Grönlund, C., Näslund, U., & Hultdin, J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.014 · Cited by 3
Nelson, J. R. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000130 · Cited by 3
Johansen, M. Ø., Vedel‐Krogh, S., Nielsen, S. F., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120605 · Cited by 4
Self-citationUllah, S., Asad, M., Ullah, F., Shah, M., Fawy, K. F., Zhang, X., Sun, W., Nishan, U., & Badshah, A. (2025) · RSC Advances · doi:10.1039/d5ra07350b · Cited by 3
Kamrani, F., Imannezhad, M., Rezaee, A. M., Darroudi, S., Kondori, A. Y., Sadatian, S., Shahri, B., Esmaily, H., Bakavoli, A. H., Ghayour‐Mobarhan, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-27681-8 · Cited by 3
Brugnara, L., García-Díez, A. I., Murillo, S., Ribalta, J., Fernández, G., Marquez, S., Rodriguez, M. A., Vinaixa, M., Amigó, N., Correig, X., et al. (2022) · European Journal of Applied Physiology · doi:10.1007/s00421-022-04929-z · Cited by 3
Khan, M. I., Zhang, Q., Tian, Y., Saud, S., Cao, Y., Ren, J., Liu, W., & Cao, C. (2023) · Analytical Methods · doi:10.1039/d3ay00550j · Cited by 3
Distinct lipoprotein contributions to valvular heart disease: Insights from genetic analysis
Luo, D., Björnson, E., Wang, X., Zhang, B., Xu, C., Guan, Y., Xiang, S., Borén, J., Hao, X., & Chen, J. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133218 · Cited by 3
Peculiar Paradoxical Results That Puzzle Me
Sniderman, A. D. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.067 · Cited by 3
Levinson, S. S. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae125 · Cited by 2
Hipertrigliceridemia (> 150 mg/dl) como marcador de riesgo cardiovascular
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500822 · Cited by 2
Qian, Y.-W., Liu, Z., Fang, F., Wang, J., Shao, X.-P., Jia, Y., Wu, X., Li, F., Zhang, W., Yang, H., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101020 · Cited by 2
Duran, E. K., Cook, N. R., Aday, A. W., Buring, J. E., Ridker, P. M., & Pradhan, A. D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.123.039381 · Cited by 2
Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
Abdalwahab, A., Al‐Atta, A., Zaman, A., & Alkhalil, M. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i9.472 · Cited by 2
Masana, L., & Ibarretxe, D. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.07.004 · Cited by 2
Afzal, S., Balling, M., Langsted, A., Smith, G. D., & Nordestgaard, B. G. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.042 · Cited by 2
Self-citationTybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
Self-citationHypertriglyceridemia (> 150 mg/dL) as a marker of cardiovascular risk
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500822 · Cited by 1
VLDL cholesterol and ASCVD risk: A population-based study
Balling, M., Roepstorff, O. G., Gerds, T. A., Varbo, A., Langsted, A., Mortensen, M. B., Smith, G. D., Nordestgaard, B. G., & Afzal, S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.024 · Cited by 1
Self-citationMaswanganyi, K., Khathi, A., & Gamede, M. W. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag036 · Cited by 1
Jang, A. Y., Kim, B. J., Jeong, Y. W., Kang, D. R., Koh, K. K., Nordestgaard, B. G., & Han, S. H. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101024 · Cited by 1
Self-citationAssociation between remnant cholesterol and peripheral artery disease from multiple perspectives
Meng, W., Wang, C., Xu, Z., Qiu, Z., Wang, H., Gu, Y., & Zhu, T. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120784 · Cited by 1
Progress in the Study of the Correlation between Apolipoproteins and Endometrial Cancer
Lou, L., & Zhu, H. (2022) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2022.1012010 · Cited by 1
Guo, X., Huang, Z., Chen, J., Hu, J., Hu, D., Peng, D., & Yu, B. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.913363 · Cited by 1
Li, L., Chou, V. H. C., Chou, O. H. I., Roy, S., Chan, J. S. K., Wong, W. T., Liu, T., Lip, G. Y. H., Cheung, B. M. Y., Tse, G., et al. (2024) · medRxiv · doi:10.1101/2024.02.08.24302507 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Hypercholesterolemia at a young age
Spiridonov, A. N., & Ragino, Y. I. (2021) · Ateroscleroz · doi:10.52727/2078-256x-2021-17-2-83-93
Magnetic resonance-assessed lipoprotein profile. The time has come for its clinical use
Masana, L., & Ibarretxe, D. (2021) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2021.07.017
Gender and cardiovascular risk in rotational shift workers in the Arctic
Петровна, Ш. Н., Ветошкин, А. С., Gapon, L., Simonyan, A. A., & Dyachkov, S. M. (2021) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2021-27-4-446-456
Shaikh, N. A., Kumar, A., Fatima, M., Hassan, A., Patel, J., & Abbas, K. (2021) · Pakistan Heart Journal · doi:10.47144/phj.v54i1.2068
Prevalencia de remanentes de colesterol aumentado en pacientes diabéticos tipo 2
Tapia, C. A., & Sonzini, L. J. (2023) · Methodo Investigación Aplicada a las Ciencias Biológicas · doi:10.22529/me.2023.8(1)03
Why Non-HDL Cholesterol is Preferred over Apolipoprotein B-100 (Apo B)Preprint
Levinson, S. S. (2023) · doi:10.32388/tulata
Research Status of Lipoprotein and Residual Risk of Cardiovascular Disease
吴, 美. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361290
Brinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24
Hedegaard, B. S. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau539425604
Multimodale kardiovaskuläre Prävention
Müller‐Wieland, D., Verket, M., Brandts, J., Jacobsen, M., Marx, N., Kanna, N. D. D., Balfanz, P., & Schütt, K. S. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_571-1
Fatima, N. (2024) · Journal of Electrical Systems · doi:10.52783/jes.3478
The Impact of Remnant Cholesterol on Cardiovascular Fitness in Young Adults: Insights from NHANESPreprint
Qin, S., Chen, J., Sun, M., & Zhang, D. (2024) · Research Square · doi:10.21203/rs.3.rs-4517007/v1
Dyslipoproteinemias in postmenopausal women and new therapeutic targets
Galván, E. E. R. (2024) · Obstetrics & Gynecology International Journal · doi:10.15406/ogij.2024.15.00755
Stationary screen time, blood lipids, and atherosclerotic cardiovascular disease incidence
Liu, Y., Xu, L., Liu, P., Liao, X., & Liao, J. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04568-0
Kelly, R. K., Tong, T. Y. N., Watling, C. Z., Reynolds, A., Piernas, C., Schmidt, J. A., Papier, K., Carter, J. L., Key, T. J., & Perez‐Cornago, A. (2024) · Figshare · doi:10.6084/m9.figshare.26564460
He, X., Zou, R., Du, X., Li, K., & Sha, D. (2024) · Figshare · doi:10.6084/m9.figshare.24946696
Okekunle, A. P., Yie, G.-E., Song, S., Kim, Z., Youn, H. J., Cho, J., Min, J. W., Kim, Y. S., & Lee, J. E. (2022) · Figshare · doi:10.6084/m9.figshare.20424049
He, X., Zou, R., Du, X., Li, K., & Sha, D. (2024) · Figshare · doi:10.6084/m9.figshare.24946372
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
Self-citationLi, Y., Wang, Y., Ma, R., Li, Z., Feng, Z., Kong, X., Zhou, Q., Guo, X., Yin, Y., Wu, Y., et al. (2026) · Food Chemistry · doi:10.1016/j.foodchem.2026.149072
Umar, M., Salim, M., Shah, A. H., & Mahrban, E. (2025) · Biological and Clinical Sciences Research Journal · doi:10.54112/bcsrj.v6i2.2269
Macario, T. M., Santos, A. C. F., Lima, N. D. S., Miranda‐Alves, L., & Santos-Silva, A. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1826776
Sun, M., Huang, R., Gao, W., Jia, X., Han, M., Miao, Y., Ning, N., Zhou, W., Wang, X., Hang, D., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109091
Lu-Zhao, W. A. N. G., Cui, K.-J., Xin-Meng, W. A. N. G., Run-Kun, J. I. A., & Xie, X. (2026) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2026.07.008
Nezhad, S. A., Nouri, A. M. E., Moreines, L. T., Mangalesh, S., Rastgou, P., Maheshwari, M., Rossi, R., Damluji, A. A., & Nanna, M. G. (2026) · Diagnostics · doi:10.3390/diagnostics16213480
Metadata
- Authors
- Balling, M., Afzal, S., Varbo, A., Langsted, A., Davey Smith, G., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Nordestgaard, Børge G.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 76
- Issue
- 23
- Pages
- 2725-2735
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3107369671
- Cited by
- 175
- References
- 61
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 39 · 2023: 35 · 2022: 24 · 2021: 39 · 2020: 1
- FWCI
- 22.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- University of Bristol (MC_UU_00011/1)
- Novo Nordisk Fonden (NNF18OC0052893)
- Hjerteforeningen (18-R124-A8511-22089)
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- apolipoprotein B, apoB-containing lipoproteins, VLDL cholesterol, VLDL triglycerides, intermediate-density lipoprotein cholesterol, LDL cholesterol, myocardial infarction risk, atherosclerotic cardiovascular disease, lipoprotein fractions, Copenhagen General Population Study, smoking, systolic blood pressure
- MeSH terms
- Aged, Apolipoproteins B, Denmark, Female, Humans, Lipoproteins, VLDL, Male, Middle Aged, Myocardial Infarction, Risk, Triglycerides, Cholesterol, VLDL, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
